Back to Journals » International Journal of Nanomedicine » Volume 6

Development of antiproliferative nanohybrid compound with controlled release property using ellagic acid as the active agent

Authors Hussein MZ, Al Ali SH, Zainal Z, Hakim MN

Published 4 July 2011 Volume 2011:6 Pages 1373—1383

DOI https://doi.org/10.2147/IJN.S21567

Review by Single-blind

Peer reviewer comments 3

Mohd Zobir Hussein1,2, Samer Hasan Al Ali2, Zulkarnain Zainal2, Muhammad Nazrul Hakim3
1Advanced Materials and Nanotechnology Laboratory, Institute of Advanced Technology (ITMA), 2Department of Chemistry, Faculty of Science, 3Department of Biomedical Science, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Selangor, Malaysia

Abstract: An ellagic acid (EA)–zinc layered hydroxide (ZLH) nanohybrid (EAN) was synthesized under a nonaqueous environment using EA and zinc oxide (ZnO) as the precursors. Powder X-ray diffraction showed that the basal spacing of the nanohybrid was 10.4 Å, resulting in the spatial orientation of EA molecules between the interlayers of 22.5° from z-axis with two negative charges at 8,8′ position of the molecules pointed toward the ZLH interlayers. FTIR study showed that the intercalated EA spectral feature is generally similar to that of EA, but with bands slightly shifted. This indicates that some chemical bonding of EA presence between the nanohybrid interlayers was slightly changed, due to the formation of host–guest interaction. The nanohybrid is of mesopores type with 58.8% drug loading and enhanced thermal stability. The release of the drug active, EA from the nanohybrid was found to be sustained and therefore has good potential to be used as a drug controlled-release formulation. In vitro bioassay study showed that the EAN has a mild effect on the hepatocytes cells, similar to its counterpart, free EA.

Keywords: ellagic acid, nonaqueous solution, ZnO, zinc-layered hydroxide, viability test

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Hippuric acid nanocomposite enhances doxorubicin and oxaliplatin-induced cytotoxicity in MDA-MB231, MCF-7 and Caco2 cell lines

Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Ismail M, Bullo S

Drug Design, Development and Therapy 2013, 7:25-31

Published Date: 14 January 2013

Comparative study of Mg/Al- and Zn/Al-layered double hydroxide-perindopril erbumine nanocomposites for inhibition of angiotensin-converting enzyme

Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Ismail M, Zainal Z, Hakim MN

International Journal of Nanomedicine 2012, 7:4251-4262

Published Date: 3 August 2012

Preparation of hippurate-zinc layered hydroxide nanohybrid and its synergistic effect with tamoxifen on HepG2 cell lines

Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Zainal Z, Hakim MN

International Journal of Nanomedicine 2011, 6:3099-3111

Published Date: 1 December 2011

Readers of this article also read:

Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials

Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M

Drug Design, Development and Therapy 2015, 9:5215-5223

Published Date: 11 September 2015

Brachytherapy in the treatment of cervical cancer: a review

Banerjee R, Kamrava M

International Journal of Women's Health 2014, 6:555-564

Published Date: 28 May 2014

Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION–EGF) for targeting brain tumors

Shevtsov MA, Nikolaev BP, Yakovleva LY, Marchenko YY, Dobrodumov AV, Mikhrina AL, Martynova MG, Bystrova OA, Yakovenko IV, Ischenko AM

International Journal of Nanomedicine 2014, 9:273-287

Published Date: 3 January 2014

Controlled gentamicin release from multi-layered electrospun nanofibrous structures of various thicknesses

Sirc J, Kubinova S, Hobzova R, Stranska D, Kozlik P, Bosakova Z, Marekova D, Holan V, Sykova E, Michalek J

International Journal of Nanomedicine 2012, 7:5315-5325

Published Date: 8 October 2012

Biosynthesis of gold nanoparticles using chloroplasts

Zhang YX, Zheng J, Gao G, Kong YF, Zhi X, Wang K, Zhang XQ, Cui DX

International Journal of Nanomedicine 2011, 6:2899-2906

Published Date: 21 November 2011

Erratum

Iancu C, Mocan L

International Journal of Nanomedicine 2011, 6:2543-2544

Published Date: 21 October 2011

Molecular network topology and reliability for multipurpose diagnosis

Jalil MA, Moongfangklang N, Innate K, Mitatha S, Ali J, Yupapin PP

International Journal of Nanomedicine 2011, 6:2385-2392

Published Date: 19 October 2011

Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles

Chen Y, Wan Y, Wang Y, Zhang H, Jiao Z

International Journal of Nanomedicine 2011, 6:2321-2326

Published Date: 18 October 2011